Case report on novel mutation in SPAST gene in Polish family with spastic paraplegia.


Journal

BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555

Informations de publication

Date de publication:
14 Dec 2019
Historique:
received: 03 10 2019
accepted: 08 12 2019
entrez: 16 12 2019
pubmed: 16 12 2019
medline: 19 3 2020
Statut: epublish

Résumé

Hereditary spastic paraplegia is a large group of degenerative, neurological disorders characterized by progressive lower limb spasticity and weakness. The disease was investigated precisely but still clinicians often make incorrect or late diagnosis. Our aim was to investigate the genetic background and clinical phenotype of spastic paraplegia in large Polish family. A 37 years old woman presented with 4-year history of walking difficulties. On neurological examination, she had signs of upper motor lesion in lower extremities. She denied sphincter dysfunction and her cognition was normal. Her family history was positive for individuals with gait problems. The initial diagnosis was familial spastic paraplegia. Genetic testing identified a novel mutation in SPAST gene. All available family members were examined and had genetic testing. The same mutation in SPAST gene was identified in other affected family members. All patients caring the mutation presented with different phenotypes. This study presents a family with spastic paraplegia due to a novel mutation c.1390G›T(p.Glu464Term) in SPAST gene. Affected individuals showed a range of phenotypes that varied in their severity. This case report demonstrates, the signs of hereditary spastic paraplegia can be often misdiagnosed with other diseases. Therefore genetic testing should always be considered in patients with lower limb spasticity and positive family history in order to help to establish the correct diagnosis.

Sections du résumé

BACKGROUND BACKGROUND
Hereditary spastic paraplegia is a large group of degenerative, neurological disorders characterized by progressive lower limb spasticity and weakness. The disease was investigated precisely but still clinicians often make incorrect or late diagnosis. Our aim was to investigate the genetic background and clinical phenotype of spastic paraplegia in large Polish family.
CASE PRESENTATION METHODS
A 37 years old woman presented with 4-year history of walking difficulties. On neurological examination, she had signs of upper motor lesion in lower extremities. She denied sphincter dysfunction and her cognition was normal. Her family history was positive for individuals with gait problems. The initial diagnosis was familial spastic paraplegia. Genetic testing identified a novel mutation in SPAST gene. All available family members were examined and had genetic testing. The same mutation in SPAST gene was identified in other affected family members. All patients caring the mutation presented with different phenotypes.
CONCLUSION CONCLUSIONS
This study presents a family with spastic paraplegia due to a novel mutation c.1390G›T(p.Glu464Term) in SPAST gene. Affected individuals showed a range of phenotypes that varied in their severity. This case report demonstrates, the signs of hereditary spastic paraplegia can be often misdiagnosed with other diseases. Therefore genetic testing should always be considered in patients with lower limb spasticity and positive family history in order to help to establish the correct diagnosis.

Identifiants

pubmed: 31837705
doi: 10.1186/s12883-019-1561-6
pii: 10.1186/s12883-019-1561-6
pmc: PMC6911268
doi:

Substances chimiques

Adenosine Triphosphatases EC 3.6.1.-
Spastin EC 3.6.4.3
SPAST protein, human EC 5.6.1.1

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

322

Références

J Neurol Sci. 2012 Jul 15;318(1-2):1-18
pubmed: 22554690
J Neurol Neurosurg Psychiatry. 2008 May;79(5):606-7
pubmed: 17971434
Brain. 2015 Sep;138(Pt 9):2471-84
pubmed: 26094131
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Sci Rep. 2019 Oct 8;9(1):14412
pubmed: 31594988
JAMA Neurol. 2013 Jun;70(6):746-55
pubmed: 23609960

Auteurs

Aleksandra Klimkowicz-Mrowiec (A)

Department of Neurology, Jagiellonian University, School of Medicine, 31-503 Krakow, Botaniczna 3, Krakow, Poland. Aleksandra.Klimkowicz@mp.pl.

Anna Dziubek (A)

Department of Neurology, University Hospital, Krakow, Poland.

Malgorzata Sado (M)

Department of Neurology, University Hospital, Krakow, Poland.

Marek Karpiński (M)

Department of Neurology, University Hospital, Krakow, Poland.

Agnieszka Gorzkowska (A)

Department of Neurology, Department of Neurorehabilitation, Medical University of Silesia, Katowice, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH